 |
80 Diseases |  |
201 Trials |
|
201 Trials |  |
5515 News |  |
| «12...58596061626364656667686970» |
- |||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: KAITLIN: A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer (clinicaltrials.gov) - Feb 27, 2017
P3, N=1846, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Feb 2018 --> Jan 2024
- |||| Prolia (denosumab) / Amgen
Enrollment open, Trial initiation date, Trial primary completion date: Denosumab as an add-on Neoadjuvant Treatment (GeparX) (clinicaltrials.gov) - Feb 23, 2017
P2, N=778, Recruiting, Sponsor: German Breast Group
Trial primary completion date: Feb 2018 --> Jan 2024 Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Dec 2018
- | paclitaxel / Generic mfg.
New P2 trial: ARETTA: Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Feb 23, 2017
P2, N=60, Not yet recruiting, Sponsor: University of Chicago
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer (clinicaltrials.gov) - Feb 14, 2017
P2, N=69, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Apr 2016 --> Feb 2017 | Trial primary completion date: Jun 2018 --> Dec 2018 Trial primary completion date: Jan 2017 --> Jan 2018
- | Avastin (bevacizumab) / Roche, Sandostatin LAR Depot (octreotide acetate) / Novartis, Perjeta (pertuzumab) / Roche
Journal: A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. (Pubmed Central) - Feb 7, 2017
Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.
- | Mytesi (crofelemer) / Jaguar Health, Knight Therap, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date: HALT-D: Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients (clinicaltrials.gov) - Feb 2, 2017
P2, N=46, Recruiting, Sponsor: Georgetown University
Results in the well-differentiated carcinoid tumors are thought provoking. Not yet recruiting --> Recruiting | Initiation date: Nov 2016 --> Jan 2017
- | Perjeta (pertuzumab) / Roche
Journal: Pertuzumab for the treatment of breast cancer: a safety review. (Pubmed Central) - Jan 31, 2017
The combination of trastuzumab, pertuzumab, and chemotherapy is approved in the neoadjuvant and first line metastatic settings and should be strongly considered by providers. Further studies are needed to look at side effect prevention, novel pertuzumab containing regimens, and re-treating patients with pertuzumab.
- ||| lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Jan 30, 2017
P1, N=66, Completed, Sponsor: Hoffmann-La Roche
Further studies are needed to look at side effect prevention, novel pertuzumab containing regimens, and re-treating patients with pertuzumab. Active, not recruiting --> Completed | N=35 --> 66
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - Jan 24, 2017
P1/2, N=46, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | N=35 --> 66 Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Sep 2017
- AST-301 / University of Washington, Aston Sci., EpiThany
Enrollment open, Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Jan 23, 2017
P1/2, N=30, Recruiting, Sponsor: University of Washington
Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Sep 2017 Suspended --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2018
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
New trial, Metastases: KNOWHER: Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=700, Not yet recruiting, Sponsor: BELEN RUIZ-ANTORAN
- ||| inavolisib (GDC-0077) / Roche
New P1 trial, Combination therapy, Metastases: GO39374: To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer (clinicaltrials.gov) - Dec 30, 2016
P1, N=156, Recruiting, Sponsor: Hoffmann-La Roche
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Dec 28, 2016
P2, N=65, Recruiting, Sponsor: City of Hope Medical Center
Suspended --> Recruiting | Trial primary completion date: Mar 2017 --> Mar 2018 Trial primary completion date: Jan 2017 --> Aug 2017
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer (clinicaltrials.gov) - Dec 28, 2016
P1, N=36, Recruiting, Sponsor: Kimberly Blackwell
Trial primary completion date: Jan 2017 --> Aug 2017 Trial primary completion date: Feb 2018 --> Feb 2019
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging (clinicaltrials.gov) - Dec 15, 2016
P2, N=150, Recruiting, Sponsor: Northwestern University
- || Verzenio (abemaciclib) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Dec 12, 2016
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Feb 2018 --> Feb 2019 Trial primary completion date: Nov 2016 --> May 2017
- Biomarker, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Dec 7, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Trial primary completion date: Nov 2016 --> May 2017 Trial primary completion date: May 2018 --> Dec 2018
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change: Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? (clinicaltrials.gov) - Dec 1, 2016
P=N/A, N=23, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: May 2018 --> Dec 2018 Recruiting --> Active, not recruiting | N=50 --> 23
- Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Enrollment closed, Enrollment change, Trial primary completion date: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Nov 14, 2016
P2, N=16, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Recruiting --> Active, not recruiting | N=50 --> 23 Suspended --> Active, not recruiting | N=70 --> 16 | Trial primary completion date: Apr 2017 --> Nov 2016
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer (clinicaltrials.gov) - Nov 2, 2016
P4, N=52, Active, not recruiting, Sponsor: Hoffmann-La Roche
Suspended --> Active, not recruiting | N=70 --> 16 | Trial primary completion date: Apr 2017 --> Nov 2016 Recruiting --> Active, not recruiting
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: PUFFIN: A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Nov 2, 2016
P3, N=240, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2019 --> Nov 2020
- |||||||||| Ibrance (palbociclib) / Pfizer
New P3 trial, Metastases: PATINA: Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (clinicaltrials.gov) - Oct 27, 2016
P3, N=496, Not yet recruiting, Sponsor: Alliance Foundation Trials, LLC.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer (clinicaltrials.gov) - Oct 27, 2016
P1/2, N=46, Recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial primary completion date: Sep 2019 --> Nov 2020 Trial primary completion date: Dec 2016 --> May 2017
- || Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Metastases: EORTC-75111-10114: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (clinicaltrials.gov) - Oct 26, 2016
P2, N=80, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Trial primary completion date: Dec 2016 --> May 2017 Trial primary completion date: May 2016 --> Dec 2016
- Perjeta (pertuzumab) / Roche, Trazimera (trastuzumab-qyyp) / Pfizer
Biomarker, Enrollment open, Trial initiation date, Surgery: NCI-2016-00570: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=20, Recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: May 2016 --> Dec 2016 Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jul 2016
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Oct 14, 2016
P2, N=32, Recruiting, Sponsor: Midwestern Regional Medical Center
Not yet recruiting --> Recruiting | Initiation date: Oct 2016 --> Jul 2016 Active, not recruiting --> Recruiting
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy in Treating Patients With Metastatic Solid Tumors (clinicaltrials.gov) - Oct 11, 2016
P1, N=36, Recruiting, Sponsor: Pravin Kaumaya
Active, not recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Trial suspension, Trial primary completion date: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Sep 30, 2016
P2, N=70, Suspended, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> Apr 2017
- | New P2 trial, Combination therapy: NeoToc: Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer (clinicaltrials.gov) - Sep 21, 2016
P2, N=78, Recruiting, Sponsor: Vejle Hospital
- | Mytesi (crofelemer) / Jaguar Health, Knight Therap, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: HALT-D: Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients (clinicaltrials.gov) - Sep 21, 2016
P2, N=46, Not yet recruiting, Sponsor: Georgetown University
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: PER-ELISA: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (clinicaltrials.gov) - Sep 19, 2016
P2, N=68, Recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> Apr 2017 Trial primary completion date: Aug 2016 --> Oct 2017
- ||| Verzenio (abemaciclib) / Eli Lilly
Enrollment open, Phase classification, Enrollment change, Combination therapy, Metastases: A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread (clinicaltrials.gov) - Sep 14, 2016
P1b, N=123, Recruiting, Sponsor: Eli Lilly and Company
Trial primary completion date: Aug 2016 --> Oct 2017 Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123
- |||||||||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P3 trial, Metastases: PUFFIN: A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Sep 12, 2016
P3, N=240, Recruiting, Sponsor: Hoffmann-La Roche
- AST-301 / University of Washington, Aston Sci., EpiThany
Trial primary completion date, IO biomarker, Metastases: Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy (clinicaltrials.gov) - Sep 7, 2016
P1/2, N=30, Suspended, Sponsor: University of Washington
Active, not recruiting --> Recruiting | Phase classification: P1 --> P1b | N=102 --> 123 Trial primary completion date: Sep 2016 --> Mar 2017
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy (clinicaltrials.gov) - Sep 2, 2016
P=N/A, N=135, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2016 --> Mar 2017 Recruiting --> Active, not recruiting | N=262 --> 135 | Trial primary completion date: Mar 2019 --> Sep 2017
- | Halaven (eribulin mesylate) / Eisai, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer (clinicaltrials.gov) - Aug 30, 2016
P2, N=32, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting | N=262 --> 135 | Trial primary completion date: Mar 2019 --> Sep 2017 Recruiting --> Active, not recruiting | N=81 --> 32
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date, Combination therapy, Metastases: Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer (clinicaltrials.gov) - Aug 8, 2016
P4, N=52, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=81 --> 32 Trial primary completion date: Apr 2019 --> Oct 2018
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial primary completion date: TRAP: Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma (clinicaltrials.gov) - Jul 28, 2016
P1/2, N=40, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial primary completion date: Apr 2019 --> Oct 2018 Trial primary completion date: Jan 2016 --> Apr 2017
- Avastin (bevacizumab) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Biomarker, Enrollment change, Trial primary completion date: Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer (clinicaltrials.gov) - Jul 23, 2016
P2, N=70, Recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Jan 2016 --> Apr 2017 N=175 --> 70 | Trial primary completion date: Jun 2016 --> Jan 2017
- ||| Kadcyla (ado-trastuzumab emtansine) / Roche, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Metastases: EORTC-75111-10114: Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1 (clinicaltrials.gov) - Jul 15, 2016
P2, N=80, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=175 --> 70 | Trial primary completion date: Jun 2016 --> Jan 2017 Recruiting --> Active, not recruiting
- Biomarker, Enrollment change, Trial primary completion date, PARP Biomarker, PD(L)-1 Biomarker: I-SPY 2: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (clinicaltrials.gov) - Jul 13, 2016
P2, N=1920, Recruiting, Sponsor: QuantumLeap Healthcare Collaborative
Recruiting --> Active, not recruiting N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018
- ganetespib (ADX-1612) / Aldeyra, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Combination therapy, Metastases: Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (clinicaltrials.gov) - Jul 12, 2016
P1, N=9, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=1200 --> 1920 | Trial primary completion date: Sep 2017 --> May 2018 Recruiting --> Active, not recruiting | N=18 --> 9
- Perjeta (pertuzumab) / Roche, Trazimera (trastuzumab-qyyp) / Pfizer
Biomarker, New trial, Surgery: NCI-2016-00570: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer (clinicaltrials.gov) - Jul 11, 2016
P=N/A, N=20, Not yet recruiting, Sponsor: City of Hope Medical Center
- ||||||| Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy: Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) (clinicaltrials.gov) - Jul 6, 2016
P3, N=208, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=18 --> 9 Active, not recruiting --> Completed
- ||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Combination therapy, Metastases: BERENICE: A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (clinicaltrials.gov) - Jul 5, 2016
P2, N=400, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- lumretuzumab (RG7116) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein (clinicaltrials.gov) - Jul 5, 2016
P1, N=35, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2016
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment change, Metastases: Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer (clinicaltrials.gov) - Jun 27, 2016
P2, N=65, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2017 --> Nov 2016 N=50 --> 65
- |||| Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion, Combination therapy, Metastases: A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer (clinicaltrials.gov) - Jun 22, 2016
P2, N=95, Completed, Sponsor: Hoffmann-La Roche
N=50 --> 65 Active, not recruiting --> Completed
- ||| Enrollment change, Tumor mutational burden, BRCA Biomarker, MSi-H Biomarker, PARP Biomarker, PD(L)-1 Biomarker, Metastases: TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (clinicaltrials.gov) - Jun 22, 2016
P2, N=1030, Recruiting, Sponsor: American Society of Clinical Oncology
Active, not recruiting --> Completed N=730 --> 1030
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment open, Trial initiation date: Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer (clinicaltrials.gov) - Jun 22, 2016
P1, N=36, Recruiting, Sponsor: Kimberly Blackwell
N=730 --> 1030 Not yet recruiting --> Recruiting | Initiation date: Feb 2016 --> May 2016